27 patents
Page 2 of 2
Utility
Emulsion Formulations of Aprepitant
24 Jun 20
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 29 Oct 19
Utility
Long-acting polymeric delivery systems
27 Apr 20
Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 20 Aug 18
Utility
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
20 Apr 20
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 26 Apr 18
Utility
Compositions of a Polyorthoester and an Aprotic Solvent
15 Apr 20
Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 16 Jul 19
Utility
Post-surgical Pain Treatment
11 Mar 20
Disclosed herein are compositions and methods for treating post-surgical pain in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a NK-1 receptor antagonist and a pain medication.
Barry D. Quart, Thomas B. Ottoboni
Filed: 5 Sep 19
Utility
Long-acting Polymeric Delivery Systems Comprising Olanzapine and a 5-HT3 Receptor Antagonist
26 Feb 20
Compositions comprised of olanzapine and a 5-HT3 receptor antagonist and a polyorthoester polymer are provided to provide extended release of the active agents.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 2 Apr 19
Utility
Emulsion formulations of aprepitant
9 Dec 19
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 4 Jan 17